Identifying high-risk triple-negative breast cancer patients by molecular subtyping

Breast CareHartung C, Porsch M, Stückrath K, et al. | October 21, 2021

Advertisement

The clinical relevance of molecular subtyping of triple-negative breast cancer [TNBC; the most aggressive type of breast cancer (BC)] in improving the individual indication of systemic therapy has been investigated.

  • From a prospective, multicenter cohort including 1,270 histopathologically confirmed invasive, non-metastatic BCs, researchers obtained 124 (82%) of 152 TNBC tumors and performed molecular subtyping on them.

  • PAM50 analysis led to identification of 87% of the tumors as basal with an inferior clinical outcome compared with patients with nonbasal tumors.

  • Twenty-three (15%) of TNBCs were identified as luminal androgen receptor (LAR) subtype using the TNBCtype-6 classifier.

  • Patients with LAR subtype can be identified via performing molecular analysis and subtyping of TNBC.

  • Given the less sensitivity of patients with LAR subtype to conventional chemotherapy, exploration of new treatment options, including androgen receptor-blocking agents and immune checkpoint inhibitors, is stressed.

Read the full article on Breast Care

Advertisement